Journal of thoracic disease · 2026
Efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in patients with tuberculosis-associated chronic obstructive pulmonary disease: study protocol for a randomised controlled trial.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wu Fan, Huang Suyin, Lei Ming, Deng Zhishan, Wan Qi, Tang Gaoying, Zhou Kunning, Liang Xiaoyan, Abduwaiti Tuxunguli, Turgon Reyihanguli, Zhang Kaiqing, Turgon Kailibinur, Li Yanni, Li Haiqing, Zou Weifeng
Аннотация
BACKGROUND: Clinical trials have shown that glycopyrrolate/formoterol fumarate improves lung function in patients with chronic obstructive pulmonary disease (COPD) caused by tobacco exposure. Although tuberculosis-associated COPD has worse respiratory health outcomes than smoking-associated COPD, no clinical trials have determined whether pharmacological intervention is effective. We designed a clinical trial to evaluate the safety and efficacy of glycopyrrolate/formoterol fumarate for the treatment of tuberculosis-associated COPD.
METHODS: We report the protocol for a prospective, multicentre, open-label, parallel-group, observer-blind, randomised clinical trial in China. Tuberculosis-associated COPD will be defined as a history of pulmonary tuberculosis and imaging manifestations, no current long-term anti-tuberculosis treatment, smoking index <10 pack-years, postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio <0.70, and FEV1 ≥50% predicted. Patients with tuberculosis-associated COPD will be randomly assigned (1:1) to the glycopyrrolate/formoterol fumarate metered dose inhaler (18 µg/9.6 µg twice daily) or no additional treatment. All patients will be provided with salbutamol as rescue medication. The primary outcome will be the between-group difference in the change from baseline to 12 weeks in prebronchodilator FEV1. The key secondary outcomes will be the between-group difference in the change from baseline to 12 weeks in postbronchodilator FEV1; percentage predicted prebronchodilator and postbronchodilator FEV1, FVC, and percentage predicted FVC; and COPD Assessment Test scores.
DISCUSSION: The results of the PTB-COPD trial will provide the first insights into the pharmacological treatment of tuberculosis-associated COPD. We anticipate the results of this trial to be available in the first half of 2027.
TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2500103088. Registered on May 23, 2025.
METHODS: We report the protocol for a prospective, multicentre, open-label, parallel-group, observer-blind, randomised clinical trial in China. Tuberculosis-associated COPD will be defined as a history of pulmonary tuberculosis and imaging manifestations, no current long-term anti-tuberculosis treatment, smoking index <10 pack-years, postbronchodilator forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio <0.70, and FEV1 ≥50% predicted. Patients with tuberculosis-associated COPD will be randomly assigned (1:1) to the glycopyrrolate/formoterol fumarate metered dose inhaler (18 µg/9.6 µg twice daily) or no additional treatment. All patients will be provided with salbutamol as rescue medication. The primary outcome will be the between-group difference in the change from baseline to 12 weeks in prebronchodilator FEV1. The key secondary outcomes will be the between-group difference in the change from baseline to 12 weeks in postbronchodilator FEV1; percentage predicted prebronchodilator and postbronchodilator FEV1, FVC, and percentage predicted FVC; and COPD Assessment Test scores.
DISCUSSION: The results of the PTB-COPD trial will provide the first insights into the pharmacological treatment of tuberculosis-associated COPD. We anticipate the results of this trial to be available in the first half of 2027.
TRIAL REGISTRATION: Chinese Clinical Trial Registry, ChiCTR2500103088. Registered on May 23, 2025.